Aeterna Zentaris Announces Director Change
August 20 2019 - 10:16PM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)
today announced that Jonathan Pollack has resigned as a director of
the Company for personal reasons, effective immediately. The board
of directors of the Company has appointed Carolyn Egbert, existing
director and Chairperson, to replace Mr. Pollack on the audit
committee.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company engaged in commercializing novel
pharmaceutical therapies, principally through out-licensing
arrangements. Aeterna Zentaris is the licensor and party to a
license and assignment agreement with Novo Nordisk A/S to carry out
development, manufacturing, registration, regulatory, and supply
chain for the commercialization of Macrilen™ (macimorelin), which
is to be used in the diagnosis of patients with adult growth
hormone deficiency in the United States and Canada. In addition, we
are actively pursuing business development opportunities for
macimorelin in the rest of the world and to monetize the value of
our non-strategic assets.
Contact:
Leslie Auld Chief Financial Officer Aeterna
Zentaris Inc. IR@aezsinc.com (843) 900-3211
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2024 to May 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From May 2023 to May 2024